Dennis Ding

Stock Analyst

(n/a)

# 4,648

Out of 4,648 analysts

10

Total ratings

n/a

Success rate

n/a

Average return

Main Sectors:

Top Industries:

Stocks Rated by Dennis Ding

	Stock	Action	Price Target	Current	Upside	Ratings	Updated
	ASMB Assembly Biosciences	Upgrades: Buy	$2 → $35	$16.98	+106.12%	1	Sep 20, 2024
	FOLD Amicus Therapeutics	Initiates: Buy	$18	$11.33	+58.87%	1	Sep 6, 2024
	ABUS Arbutus Biopharma	Maintains: Buy	$5 → $7	$3.87	+80.88%	2	Sep 5, 2024
	RXRX Recursion Pharmaceuticals	Maintains: Hold	$8 → $6	$6.64	-9.64%	1	Sep 3, 2024
	LYRA Lyra Therapeutics	Downgrades: Hold	$10 → $0.5	$0.26	+90.19%	1	May 7, 2024
	CARA Cara Therapeutics	Reiterates: Buy	$18	$0.29	+6,068.61%	1	Jun 27, 2023
	CORT Corcept Therapeutics	Downgrades: Hold	$35 → $22	$50.06	-56.05%	1	Feb 15, 2023
	NAMS NewAmsterdam Pharma Company	Initiates: Buy	$24	$18.03	+33.11%	1	Dec 19, 2022
	ROIV Roivant Sciences	Initiates: Buy	$10	$11.53	-13.27%	1	Oct 26, 2021

Assembly Biosciences

Sep 20, 2024

Upgrades: Buy

Price Target: $2 → $35

Current: $16.98

Upside: +106.12%

Amicus Therapeutics

Sep 6, 2024

Initiates: Buy

Price Target: $18

Current: $11.33

Upside: +58.87%

Arbutus Biopharma

Sep 5, 2024

Maintains: Buy

Price Target: $5 → $7

Current: $3.87

Upside: +80.88%

Recursion Pharmaceuticals

Sep 3, 2024

Maintains: Hold

Price Target: $8 → $6

Current: $6.64

Upside: -9.64%

Lyra Therapeutics

May 7, 2024

Downgrades: Hold

Price Target: $10 → $0.5

Current: $0.26

Upside: +90.19%

Cara Therapeutics

Jun 27, 2023

Reiterates: Buy

Price Target: $18

Current: $0.29

Upside: +6,068.61%

Corcept Therapeutics

Feb 15, 2023

Downgrades: Hold

Price Target: $35 → $22

Current: $50.06

Upside: -56.05%

NewAmsterdam Pharma Company

Dec 19, 2022

Initiates: Buy

Price Target: $24

Current: $18.03

Upside: +33.11%

Roivant Sciences

Oct 26, 2021

Initiates: Buy

Price Target: $10

Current: $11.53

Upside: -13.27%